Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Sciences Ltd.

Division of Roivant Sciences GMBH
www.axovant.com

Latest From Axovant Sciences Ltd.

Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio

Respivant will be Roivant's 13th "vant," focused on developing what was Patara Pharma's mast cell stimulator for chronic cough in patients with idiopathic pulmonary fibrosis. Former Patara CEO Bill Gerhart will lead the firm.

Deals Research and Development Strategies

Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Financing StartUps and SMEs

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Deals Commercial

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences GMBH
  • Senior Management
  • Pavan Cheruvu, MD, CEO
    Gregory M Weinhoff, MD, CFO
    Fraser Wright, PhD, CTO
    Shankar Ramaswamy, MD, SVP, Bus. Dev.
    Gavin Corcoran, MD, EVP, R&D
    Ilise Lombardo, MD, SVP, Clinical Research
  • Contact Info
  • Axovant Sciences Ltd.
    Phone: 203 318 9708
    11-12 St. James’s Square
    Ste. 1, 3rd Fl.
    London, SW1Y 4LB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register